Immunological therapeutic - Radiant Biotherapeutics
Latest Information Update: 31 Oct 2025
At a glance
- Originator Radiant Biotherapeutics
- Class Antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 17 Sep 2025 Early research in Immunological disorders in Canada (Parenteral) (Radiant Biotherapeutics pipeline, September 2025)